The research, led by Ming Hao and Longping Liu under the corresponding authorship of Jianbin Wang, focuses on granulosa cells, the somatic cells that surround the oocyte and sustain its growth. Granulosa cell apoptosis, the team notes, initiates a considerable portion of follicular atresia, making these cells the natural place to look for the molecular switches of follicle death. The investigators’ earlier work had already identified the hypoxia-inducible factor 1 pathway, activated by follicle-stimulating hormone, as a protective factor that guards follicles against atresia. What remained unclear was precisely how that protection works, and how it interacts with the known pro-apoptotic forces inside the ovary.

To answer that question, the team adopted a methodological approach that sets the study apart from much of the existing literature. Rather than pooling many follicles together and averaging their molecular profiles, they employed a single-follicle, multi-dimensional profiling strategy based on serial sectioning. This allowed them to dissect the signaling logic underlying physiological follicle fate decisions follicle by follicle, preserving the spatial and individual variation that bulk analyses tend to erase. The technical toolkit behind the study included immunofluorescence, laser capture microdissection, and TUNEL labeling to detect apoptotic cells, alongside markers of oxidative stress such as 4-hydroxynonenal, 8-hydroxyguanosine, and 3-nitrotyrosine, which report lipid peroxidation, DNA oxidation, and protein nitration respectively.

The central finding is a striking complementarity. In the granulosa cells of healthy, growing mouse follicles, the HIF1 pathway is active, while in atretic follicles, those destined for destruction, it is the forkhead box protein O1 pathway that dominates. FOXO1 is a well-known transcription factor in the apoptosis field, capable of driving expression of pro-death genes including Bim, a member of the BH3-only family that pushes cells toward self-destruction. The observation that HIF1 and FOXO1 activation patterns are mutually exclusive across healthy and dying follicles suggests that the two pathways do not merely coexist in granulosa cells but actively compete to set the cell’s course.

Perhaps the most provocative element of the study concerns reactive oxygen species. ROS are often cast as villains in biology, the corrosive byproducts of metabolism that damage DNA, proteins, and membranes. Yet the researchers found that in growing mouse follicles, HIF1 pathway activity is associated with increased ROS-related signals, likely a consequence of enhanced granulosa-cell metabolic activity. Far from being a harbinger of doom, these ROS signals appear under physiological conditions to help maintain HIF1 pathway activity in granulosa cells during follicle growth. Crucially, the team reports that ROS-related signals are not by themselves associated with follicle atresia, a finding that complicates the simple oxidative-stress narrative and instead frames moderate ROS production as part of the metabolic engine that keeps a follicle alive and growing.

How, then, does HIF1 translate its activity into survival? The study’s answer lies in Bcl-XL, short for B-cell lymphoma-extra large, a canonical anti-apoptotic protein that works at the mitochondrial level to prevent the cascade of events leading to programmed cell death. The researchers present evidence that the HIF1 pathway appears to promote Bcl-XL expression in granulosa cells. This pro-survival output, they propose, may counterbalance the FOXO1-associated atretic pressure, the constant push toward apoptosis that FOXO1 and its downstream target Bim exert on the follicle. In other words, the follicle’s fate may hinge on which arm of this transcriptional contest wins control of the cell’s mitochondrial life-or-death machinery.

The authors synthesize these observations into a model of follicular fate as a dynamic balance between two axes: the pro-survival HIF1/Bcl-XL axis and the pro-apoptotic FOXO1/Bim axis. When HIF1 activity is sustained, supported in part by the ROS generated through active granulosa-cell metabolism, Bcl-XL expression holds the apoptotic machinery in check and the follicle continues to grow. When HIF1 activity wanes and FOXO1 takes over, Bim rises, Bcl-XL’s protective grip loosens, and the follicle slides into atresia. This framing transforms atresia from a passive failure into an active tug-of-war, one that can in principle be tipped in either direction by changes in hormonal signaling, metabolic state, or oxygen availability.

The experimental design reinforces the credibility of this model. The team used pregnant mare serum gonadotropin to stimulate follicle growth in mice and echinomycin, a pharmacological inhibitor of HIF1, to perturb the pathway experimentally, alongside N-acetyl-L-cysteine to modulate ROS levels. The use of Foxl2-CreER mice, obtained as a kind gift from Kui Liu’s laboratory at the University of Hong Kong Shenzhen Hospital, allowed granulosa-cell-specific manipulation. All animal experiments were approved by the Institutional Animal Care and Use Committee of Tsinghua University. The work was supported by the National Natural Science Foundation of China, and the authors declare no competing interests.

It is worth emphasizing what the study does and does not claim. The language of the paper is deliberately measured: HIF1 pathway activity is associated with Bcl-XL expression, and the balance model is presented as an association-based framework rather than a fully resolved causal chain. The findings are rooted in mouse ovaries, and while the conservation of HIF1, FOXO1, Bcl-XL, and Bim across mammals suggests the logic may generalize, direct evidence in human ovaries remains to be established. The authors themselves frame their conclusion as a description of what follicular fate appears to be associated with, a caution appropriate for a system as complex as the ovarian follicle, where endocrine, paracrine, and metabolic signals all converge.

Even with those caveats, the implications are considerable. Follicular atresia sits at the heart of some of the most consequential questions in reproductive biology: how the ovarian reserve is spent over a lifetime, why some follicles are selected while others are discarded, and how conditions such as polycystic ovary syndrome, a subject the journal explicitly links to this work, disrupt follicle selection. A clearer mechanistic understanding of the HIF1/Bcl-XL and FOXO1/Bim axes provides researchers with a defined set of molecular levers to investigate in these contexts. If the balance identified in mouse ovaries proves relevant to human follicle dynamics, it could eventually inform strategies aimed at preserving ovarian function, improving assisted reproduction outcomes, or extending fertility. For now, the study stands as a vivid demonstration that a follicle’s survival is not a matter of chance but of a measurable, contestable molecular equilibrium, one that science is only beginning to read in full.

Subject of Research: The molecular regulation of ovarian follicle atresia by the opposing HIF1/Bcl-XL survival and FOXO1/Bim apoptotic signaling axes in mouse granulosa cells

Article Title: HIF1 counteracts FOXO1/Bim-associated follicle atresia in mouse ovaries by promoting Bcl-XL expression

Article References: Hao, M., Liu, L., & Wang, J. (2026). HIF1 counteracts FOXO1/Bim-associated follicle atresia in mouse ovaries by promoting Bcl-XL expression. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02284-7

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02284-7

Keywords: follicle atresia, granulosa cells, HIF1 pathway, FOXO1, Bcl-XL, Bim, apoptosis, reactive oxygen species, ovarian follicles, fertility, follicle selection, Journal of Ovarian Research

Collagen peptides are short chains of amino acids produced by enzymatically breaking down collagen from skin, bone, and cartilage. They have attracted attention for antioxidant, antihypertensive, and anti-aging properties, and previous work has shown that proline- and arginine-rich sequences at their C-terminal ends can inhibit dipeptidyl peptidase-IV (DPP-IV), an enzyme whose suppression prolongs the action of incretin hormones that stimulate insulin release. But the researchers argue that hitting DPP-IV alone is often not enough. Persistent hyperglycemia fuels overproduction of reactive oxygen species, and when antioxidant defenses falter, the resulting oxidative stress damages pancreatic beta cells, muddles insulin signaling, and derails glucose handling in the liver, accelerating the progression of type 2 diabetes.

To find a suitable partner for the peptides, the team screened four plant extracts, from blue plum, tremella, mulberry leaf, and bitter melon, alongside the cowhide collagen peptides themselves. In radical-scavenging assays, bitter melon extract stood out: its DPPH radical scavenging activity was nearly five times that of the collagen peptides, and its hydroxyl radical scavenging capacity exceeded the peptides by more than 85 percent. It also showed a stronger, though statistically not significant, tendency to inhibit alpha-amylase, the digestive enzyme that cleaves dietary starch into sugars. That dual profile, antioxidant power plus suppression of carbohydrate breakdown, made bitter melon the natural candidate for a combination formulation.

The interaction between the two components turned out to be a genuine molecular partnership rather than a simple mixture. Fluorescence spectroscopy showed that as bitter melon extract concentration rose, the peptides’ fluorescence was progressively quenched, and Stern-Volmer analysis indicated static quenching, meaning the two had formed non-fluorescent complexes. Thermodynamic calculations revealed positive enthalpy and entropy changes and negative free energy, signatures of a spontaneous, endothermic binding process driven primarily by hydrophobic interactions. Molecular docking of two representative collagen peptides, GPVGPPG and GPVG, against momordicine I, a key bioactive constituent of the extract, confirmed that hydrogen bonds and hydrophobic pi-alkane and pi-sigma contacts stabilize the assembly. Infrared spectroscopy and calorimetry backed this up: the amide I and amide II bands of the peptides shifted after binding, and the complex melted at higher temperatures, indicating enhanced thermal stability. Microscopy even showed the fragments reassembling into larger, flake-like structures.

What matters most for an oral supplement, however, is survival in the gut. The researchers subjected both the plain peptides and the complex to simulated gastric and intestinal digestion. Both withstood pepsin admirably, retaining over 80 percent of their activities. But trypsin in the intestinal phase proved far more destructive, significantly degrading the bioactivity of the plain peptides. The bitter melon complex, by contrast, retained significantly higher alpha-amylase inhibition and antioxidant capacity after intestinal digestion, suggesting the molecular partnership shields the peptides from enzymatic attack. Notably, DPP-IV inhibition was no different between the two after digestion, likely because continued hydrolysis of the proline-rich peptides keeps generating new DPP-IV-inhibiting fragments regardless.

Then came the animal trial. The team induced type 2 diabetes in mice with a high-sugar, high-fat diet followed by streptozocin injections, then treated the diabetic animals for four weeks with collagen peptides, the peptide-bitter melon combination, or metformin as a positive control. After four weeks, fasting blood glucose fell by nearly 38 percent in the peptide group and about 39 percent in the combination group, compared with roughly 52 percent for metformin. Glucose tolerance improved in both treatment groups, again with a slight edge for the combination, as measured by a standard oral glucose tolerance test.

The combination also tackled oxidative stress more effectively. Diabetic mice showed depressed total antioxidant capacity and reduced activities of glutathione peroxidase and superoxide dismutase in the liver, along with elevated malondialdehyde, a marker of lipid damage. Peptide supplementation partially reversed these changes, and the combination pushed them further toward normal, consistent with the in vitro radical-scavenging results. The liver told a similar story structurally: diabetic mice had depleted hepatic glycogen stores, swollen and vacuolated hepatocytes, and disrupted kidney tubules, all of which improved after treatment, with the combination group showing the clearest restoration of glycogen deposition and tissue architecture.

Mechanistically, the benefits appear to route through a well-known metabolic control axis. AMP-activated protein kinase, or AMPK, is a master sensor of cellular energy status whose activation suppresses hepatic gluconeogenesis, the liver’s internal production of new glucose. In the diabetic mice, the phosphorylation ratio of AMPK was significantly depressed. Both treatments restored it, with the combination showing the strongest effect, while simultaneously reducing the expression of FoxO1, a transcription factor that drives gluconeogenic genes, and PEPCK, the rate-limiting enzyme of that process. In other words, the supplement combination seems to flip the liver from a glucose-producing state toward a glucose-storing one.

The study also ventured into the gut microbiome, sequencing bacterial DNA from cecal contents and profiling cecal metabolites by untargeted metabolomics. Diabetic mice exhibited an elevated ratio of Firmicutes to Bacteroidetes, reduced microbial diversity, and shifts in genera such as Candidatus Arthromitus and Anaerostipes. The combination treatment partially reversed these dysbiotic patterns and shifted the overall community composition toward that of healthy controls. Metabolomics revealed 89 significantly altered metabolites, including stress-related steroid hormones like cortisol and aldosterone, which rose with diabetes and fell back toward normal with treatment, along with antioxidant compounds like ascorbate that were depleted in disease and partially restored. Association analysis linked these metabolic shifts to specific microbial phyla, hinting that the gut ecosystem participates in the formulation’s effects.

The authors are careful to frame the microbiota findings as correlational, offering mechanistic clues rather than proof of a causal host-microbe pathway, and the work remains at the mouse-model stage, with human efficacy, dosing, and safety still untested. Yet the study makes a compelling case that food-derived ingredients can be engineered into something greater than the sum of their parts. By pairing waste-stream collagen with a traditional medicinal plant, and letting noncovalent chemistry, digestive stability, AMPK signaling, and gut ecology all pull in the same direction, the researchers suggest that the future of glycemic management may partly lie not in a single magic molecule, but in thoughtfully assembled natural complexes. If subsequent studies confirm these effects in humans, cowhide, one of the meat industry’s most abundant leftovers, could find itself at the center of a new generation of functional foods for blood sugar control.

Subject of Research: Antihyperglycemic effects of cowhide collagen peptides combined with Momordica charantia extract in type 2 diabetes

Article Title: Enhanced antihyperglycemic effects of cowhide collagen peptides by the combination with Momordica charantia extract: AMPK–FoxO1 pathway engagement and gut microbiota remodeling

Article References: He, L., Wang, X., He, J., Gao, Y., Yu, Q., & Zhang, L. (2026). Enhanced antihyperglycemic effects of cowhide collagen peptides by the combination with Momordica charantia extract: AMPK–FoxO1 pathway engagement and gut microbiota remodeling. Journal of Agriculture and Food Research, 31, Article 103298. https://doi.org/10.1016/j.jafr.2026.103298

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103298

Keywords: collagen peptides, bitter melon, Momordica charantia, type 2 diabetes, AMPK, FoxO1, gut microbiota, antioxidant, DPP-IV, alpha-amylase, hepatic gluconeogenesis, functional foods

The researchers built their investigation around one of the most widely used models of cellular inflammation. They treated RAW264.7 macrophages, a mouse immune cell line, with lipopolysaccharide, or LPS, a molecule derived from the outer membrane of certain bacteria that reliably provokes a fierce inflammatory response. LPS exposure mimics the molecular alarm bells that ring during infection and tissue injury, and it is a standard tool for probing how immune cells behave when the body’s danger signals are blazing. Within this model, the team set out to dissect what happens when the balance between two key proteins, SIRT1 and FOXO1, is disturbed.

SIRT1 is a deacetylase enzyme, a member of the sirtuin family that has long been associated with cellular longevity, metabolic regulation and stress resistance. It works chemically by removing acetyl groups from target proteins, altering their activity. FOXO1, meanwhile, is a transcription factor, a DNA-binding protein that switches genes on and off. Previous work had hinted that SIRT1 could modify FOXO1 and influence its function, but the downstream consequences for mitochondrial quality control and immune cell metabolism remained incompletely understood. The new study set out to test whether SIRT1 restrains FOXO1 and, in doing so, protects cells from runaway inflammation.

To manipulate the pathway, the researchers used molecular tools to silence SIRT1 or to force cells to overexpress FOXO1. Both interventions produced strikingly similar effects, revealing that SIRT1 normally acts upstream to hold FOXO1 in check. When SIRT1 was knocked down, or when FOXO1 was artificially elevated, the cells dramatically increased production of PINK1 and Parkin, the two central proteins of the mitophagy machinery. Mitophagy is the process by which cells identify damaged mitochondria and tag them for destruction and recycling, and PINK1 and Parkin are the quality-control officers who flag defective organelles for removal. In principle, mitophagy is beneficial, clearing out dysfunctional power plants before they leak harmful reactive molecules. But the study showed that too much of a good thing can be toxic.

With PINK1 and Parkin ramped up excessively, the macrophages suffered a collapse of mitochondrial membrane potential, the electrical gradient across the inner mitochondrial membrane that drives energy production. Using the JC-1 fluorescent probe, the team visualized this dissipation directly, finding that the cells’ cellular power stations were losing their charge. The consequences rippled outward. The cells released elevated amounts of tumor necrosis factor-alpha and interleukin-1 beta, two potent inflammatory cytokines that amplify immune responses and can damage surrounding tissue. Levels of malondialdehyde, a widely used marker of oxidative lipid damage, also climbed, indicating that the cells were under heavy oxidative stress. In short, the SIRT1-FOXO1 imbalance pushed the macrophages into a hyperinflammatory state.

The metabolic rewiring was equally dramatic. The team measured glucose uptake, lactate production and ATP levels, and all three rose when the axis was disrupted. Key glycolysis-related proteins were upregulated, pointing to a shift toward aerobic glycolysis, the glucose-burning mode famously favored by rapidly dividing and highly activated immune cells. This metabolic switch, sometimes called the Warburg-like state, allows activated macrophages to generate building blocks and rapid bursts of energy even when oxygen is plentiful. But it came at a cost: the cellular microenvironment became acidified, as the surplus glucose was converted into lactate and exported from the cells. The combination of cytokine flooding, oxidative damage and acidic surroundings paints a picture of a tissue environment primed for injury.

To confirm that these changes were driven by the autophagy machinery itself, the researchers deployed two pharmacological modulators acting at different points in the autophagy pathway. Rapamycin, an inhibitor of the mTOR pathway and a well-established enhancer of autophagy, further intensified the phenotypes triggered by the SIRT1-FOXO1 imbalance, worsening membrane potential loss and inflammatory output. Conversely, 3-methyladenine, known as 3-MA, which blocks an early step of autophagosome formation, attenuated the same phenotypes. This push-pull experiment provides mechanistic weight to the central claim: the inflammatory and metabolic damage observed when SIRT1 is silenced or FOXO1 is elevated flows substantially through excessive activation of mitophagy and the associated metabolic shift.

The broader significance of the work lies in its implications for the brain. Macrophage-like immune cells, including the brain’s resident microglia and infiltrating macrophages, are central players in neuroinflammation, the chronic or excessive inflammatory response within nervous tissue that accompanies ischemic stroke, traumatic brain injury and neurodegenerative disease. If the SIRT1-FOXO1 axis functions similarly in these cells, then bolstering SIRT1 activity or damping FOXO1 signaling could help keep mitochondrial quality control within healthy bounds, preserving energy metabolism and reducing the release of cytokines that injure vulnerable neurons. The authors propose that this pathway may represent a potential therapeutic target for neuroinflammatory diseases such as ischemic stroke, where limiting secondary inflammatory damage is a major unmet clinical need.

The study, conducted by researchers affiliated with the Second Affiliated Hospital of Xi’an Jiaotong University and the Affiliated Hospital of Yan’an University, was supported by the Yan’an Science and Technology Plan and the Shaanxi Provincial Health and Wellness Research Innovation Platform. As with all cell-line work, important caveats remain. RAW264.7 macrophages are a laboratory model, and the behavior of these engineered cells must be validated in primary cells, in animal models of stroke and eventually in human tissue before any clinical translation can occur. The doses of LPS and the genetic manipulations used in vitro do not perfectly reproduce the complex inflammatory milieu of a diseased brain. Nevertheless, the study offers a clear and testable model: SIRT1 negatively regulates FOXO1, and this restraint prevents excessive mitophagy, preserves mitochondrial membrane potential, restrains the glycolytic shift and keeps inflammatory cytokine release in check. For a field searching for ways to quiet the immune storm that follows brain injury, that model is a compelling roadmap for the next generation of experiments.

Subject of Research: The SIRT1-FOXO1 signaling axis regulates mitophagy and glycolytic metabolism in LPS-stimulated macrophages with implications for neuroinflammation.

Article Title: SIRT1/FOXO1 axis regulates mitophagy and glycolytic metabolism in LPS-stimulated macrophages: implications for neuroinflammation

Article References: Yang, X., Ai, X., Sun, H., & Shi, W. (2026). SIRT1/FOXO1 axis regulates mitophagy and glycolytic metabolism in LPS-stimulated macrophages: implications for neuroinflammation. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01038-x

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01038-x

Keywords: SIRT1, FOXO1, mitophagy, macrophages, glycolysis, neuroinflammation, LPS, inflammatory cytokines, ischemic stroke, mitochondrial membrane potential, PINK1, Parkin